Hermann L Müller1. 1. Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Rahel-Straus-Strasse 10, 26133, Oldenburg, Germany. mueller.hermann@klinikum-oldenburg.de.
Abstract
PURPOSE: This report is a review of findings on the diagnosis, treatment, clinical course, follow-up, and prognosis of craniopharyngioma patients with special regard to clinical trials and long-term management. METHODS: Literature search on Pubmed for paper published after 1994. RESULTS: Craniopharyngiomas are rare, embryonic malformations of the sellar/parasellar region with low histological grade. Clinical manifestations are related to increased intracranial pressure, visual impairment, and hypothalamic/pituitary deficiencies. If the tumor is favorably localized, therapy of choice is complete resection, with care taken to preserve hypothalamic and optic functions. In patients with unfavorable tumor location (i.e. involvement of hypothalamic areas), recommended therapy is limited hypothalamus-sparing surgical strategy followed by irradiation. Irradiation has proven effective in treatment of recurrences and progression. Surgical lesions and/or anatomical involvement of posterior hypothalamic areas can result in serious sequelae, mainly hypothalamic syndrome. CONCLUSIONS: It is crucial that craniopharyngioma be managed as a frequently chronic disease, providing ongoing care of pediatric and adult patients' by experienced multidisciplinary teams in the context of multicenter trials.
PURPOSE: This report is a review of findings on the diagnosis, treatment, clinical course, follow-up, and prognosis of craniopharyngiomapatients with special regard to clinical trials and long-term management. METHODS: Literature search on Pubmed for paper published after 1994. RESULTS: Craniopharyngiomas are rare, embryonic malformations of the sellar/parasellar region with low histological grade. Clinical manifestations are related to increased intracranial pressure, visual impairment, and hypothalamic/pituitary deficiencies. If the tumor is favorably localized, therapy of choice is complete resection, with care taken to preserve hypothalamic and optic functions. In patients with unfavorable tumor location (i.e. involvement of hypothalamic areas), recommended therapy is limited hypothalamus-sparing surgical strategy followed by irradiation. Irradiation has proven effective in treatment of recurrences and progression. Surgical lesions and/or anatomical involvement of posterior hypothalamic areas can result in serious sequelae, mainly hypothalamic syndrome. CONCLUSIONS: It is crucial that craniopharyngioma be managed as a frequently chronic disease, providing ongoing care of pediatric and adult patients' by experienced multidisciplinary teams in the context of multicenter trials.
Authors: Sung Ho Moon; Il Han Kim; Seok Won Park; Inah Kim; Semie Hong; Charn Il Park; Kyu Chang Wang; Byung Kyu Cho Journal: Childs Nerv Syst Date: 2005-06-14 Impact factor: 1.475
Authors: Andrea Poretti; Michael A Grotzer; Karin Ribi; Eugen Schönle; Eugen Boltshauser Journal: Dev Med Child Neurol Date: 2004-04 Impact factor: 5.449
Authors: A Bereket; W Kiess; R H Lustig; H L Muller; A P Goldstone; R Weiss; Y Yavuz; Z Hochberg Journal: Obes Rev Date: 2012-05-11 Impact factor: 9.213
Authors: Mohammed A Fouda; David Zurakowski; R Michael Scott; Karen J Marcus; Peter E Manley; Nicole J Ullrich; Laurie E Cohen; Liliana C Goumnerova Journal: Childs Nerv Syst Date: 2020-09-04 Impact factor: 1.475
Authors: M Azuma; Z A Khant; M Kitajima; H Uetani; T Watanabe; K Yokogami; H Takeshima; T Hirai Journal: AJNR Am J Neuroradiol Date: 2019-12-19 Impact factor: 3.825
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702